Physician profile
Roy Gill
NPI 1831190867
$8,615.38
in general payments reported to CMS, 2019-2025
35 companies · $1,114 in 2025
The $1,114 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,110 · 2020: $871 · 2021: $399 · 2022: $298 · 2023: $932 · 2024: $1,892 · 2025: $1,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,937.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,066.91 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $887.72 | 2019-2025 | Arexvy |
| Viiv Healthcare Company | $635.59 | 2019-2025 | Dovato, Apretude, Rukobia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $635.46 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Abbvie INC. | $562.04 | 2019-2025 | |
| Amgen INC. | $521.42 | 2019-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $441.37 | 2019-2024 | |
| Novo Nordisk INC | $419.68 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $356.63 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $353.58 | 2019-2024 | Verquvo, Belsomra |
| Amarin Pharma, INC. | $321.97 | 2019-2020 | |
| Allergan, INC. | $301.80 | 2019-2020 | |
| Pfizer INC. | $291.93 | 2019-2025 | |
| Abbott Laboratories | $236.32 | 2019-2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $234.80 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $232.40 | 2019-2024 | Invega Trinza, Invega Sustenna |
| Gilead Sciences, INC. | $213.73 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $164.30 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $133.37 | 2020 | |
| Indivior INC. | $101.38 | 2019-2025 | Sublocade |
| Emd Serono, INC. | $73.43 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $69.64 | 2024-2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.92 | 2025 | Caplyta |
| Daiichi Sankyo INC. | $41.68 | 2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $40.28 | 2023 | |
| Neurocrine Biosciences, INC. | $34.39 | 2024 | Ingrezza |
| Verona Pharma, INC. | $28.85 | 2025 | Ohtuvayre |
| Halozyme INC | $25.98 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.01 | 2019 | |
| Alkermes, INC. | $21.90 | 2025 | Vivitrol |
| Theratechnologies INC. | $19.84 | 2019 | |
| Sunovion Pharmaceuticals INC. | $18.22 | 2020 | |
| Ironwood Pharmaceuticals, INC | $16.19 | 2019 | |
| Axsome Therapeutics, INC. | $14.31 | 2025 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $13.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Gill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.